Delving into the Latest Updates on anti-GPC3 CAR T(Shanghai Renji Hospital) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms-

Target

GPC3

Action

inhibitors

Mechanism

GPC3 inhibitors(Glypican-3 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication-

Inactive Indication

Advanced Hepatocellular Carcinoma

Originator Organization

Shanghai Renji Hospital Management Co., Ltd.

Active Organization-

Inactive Organization

Shanghai Renji Hospital Management Co., Ltd.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

This study is designed to determine the safety and efficacy of CAR-GPC3 T cells in patients with relapsed or refractory hepatocellular carcinoma. Single or multiple doses of GPC3-targeted CAR T cells will be given to subjects with unmet medical needs for which there are no effective therapies known at this time.

Start Date17 Mar 2017

Sponsor / Collaborator

Shanghai Renji Hospital Management Co., Ltd.

[+1]

NCT02395250

/ CompletedPhase 1

Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).

Start Date01 Mar 2015

Sponsor / Collaborator

Shanghai Renji Hospital Management Co., Ltd.

100 Clinical Results associated with anti-GPC3 CAR T(Shanghai Renji Hospital)

Login to view more data

100 Translational Medicine associated with anti-GPC3 CAR T(Shanghai Renji Hospital)

Login to view more data

100 Patents (Medical) associated with anti-GPC3 CAR T(Shanghai Renji Hospital)

Login to view more data

1

Literatures (Medical) associated with anti-GPC3 CAR T(Shanghai Renji Hospital)

01 Sep 2023·Cancer communications (London, England)

Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy

Letter

Author: Siying Wang ; Bo Zhai ; Jiachang Chi ; Haojie Jin ; Zonghai Li ; Dan Cui ; Donghua Shi ; Yaoping Shi ; Yan Lin ; Xiaoyin Tang

100 Deals associated with anti-GPC3 CAR T(Shanghai Renji Hospital)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	Phase 1	China	Shanghai Renji Hospital Management Co., Ltd.	01 Mar 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02395250 (Literature) Manual	Phase 1	Advanced Hepatocellular Carcinoma	2	anti-GPC3 CAR T	onosvsgqur(eladxzpbns) = For case 1: overall survival time more than 8 years; For case 2: disease-free for more than 5 years without any further anticancer treatment and has an overall survival time of over 8 years. mbgwxuqumj (vqbonantfq )	Positive	21 Jul 2023